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Abstract. Background/Aim: Studies comparing health-
related quality of life (HR-QoL) between patients who
underwent radical cystectomy (RC) and those who underwent
a different form of urinary diversion has not reached yet
univocal and reliable conclusions. The aim of our study was
to evaluate bladder-specific long-term HR-QoL after radical
cystectomy and ileal conduit. Patients and Methods: A
multicenter study was carried out on 145 consecutive patients
(112 males and 33 females) undergoing RC and ileal conduit
(IC). HR-QoL assessment was conducted using Italian
versions of European Organisation for Research and
Treatment of Cancer QLQ-C30 and EORTC BLM-30
questionnaires. Results: Our data showed that women who
underwent IC presented greater problems than men in
cognitive functioning (mean score±SD: 77.3±27.9 vs.
87.8±18.6) as well in future perspective (score: 42.4±34.4 vs.
21.9±24.6). Nevertheless, men undergoing IC had more
problems in sexual functioning than women (score: 23.3±24.5
vs. 7.0±20.3) (all p<0.05). Conclusion: In our series, female
patients presented a greater burden than male patients in
cognitive functioning as well in future perspective, but lower
concerns with regard to sexual function.
Bladder cancer is one of the most commonly diagnosed types
of cancer and Europe has the highest incidence rate of
bladder cancer worldwide. Morevover, Spain and Italy have
the highest incidence in men in Europe, at approximately
37/100,000 and 33/100,000. respectively, (1). Classically,
according to European Association of Urology (EAU)
Guidelines, radical cystectomy (RC) represents the gold
standard treatment for muscle-invasive bladder cancer, T2-
T4a, N0-Nx, M0 and for high-risk and recurrent superficial
tumours (2). Unfortunately, no consensus has been reached
about ideal age, timing and type of urinary diversion after
RC. Options range from ileal conduit (IC) to orthotopic
neobladder (ONB) reconstruction, with different outcomes,
such as complication rates and health-related quality of life
(HR-QoL). Studies comparing HR-QoL between radical
cystectomy and different urinary diversion has not reached
yet univocal and reliable conclusions. Nevertheless, in a
recent meta-analysis of non-randomized comparative studies,
Cerruto et al. demonstrated a significant advantage of ileal
ONB compared to IC in terms of HR-QoL (3). On the other
hand, a recent review conducted by Yang et al. failed to
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demonstrate a significant difference between patients after
IC and ONB, even showing a small benefit for physical
health with IC (4). According to Cerruto et al., findings
regarding IC show patient satisfaction seems to be related to
the degree of adaptation to their new life with an IC, a new
phase of life and not simply a deterioration (5).
The aim of this study was to evaluate bladder-specific
long-term HR-QoL after RC and IC and to assess whether
HR-QoL outcomes differ between men and women.
Patients and Methods 
A multicentre study was carried out on 145 consecutive patients
(112 males and 33 females) undergoing RC and IC for bladder
cancer at five Italian academic urological centres (Verona, Trieste,
Naples Federico II, Padua and Rome Catholic University), from
June 2007 to December 2013. Patients were invited to participate
in the study at their follow-up medical consultation and gave their
signed informed consent.
All the patients included in our study underwent RC and IC due
to oncological indication and were affected by muscle-invasive
bladder cancer or had non-responding high-grade non-muscle-
invasive bladder cancer according to EAU Guidelines (2).
Moreover, all patients underwent RC with pelvic and iliac lymph
node dissection with radical en bloc cystectomy as described by
Skinner and Lieskovsky (6), and were between 18-95 years of age,
with a sufficient educational level and command of the italian
language sufficient to understand and fill out a questionnaire.
Patients who were not capable of completing a questionnaire, or had
a history of psychiatric disorders, alcohol or substance abuse,
difficulties in verbal or written communication, non-Italian
speakers, as well as those who had cognitive deterioration, were
excluded from the study. Moreover, all the included patients had no
evidence of disease recurrence and were actively followed-up.
Data obtained from the retrospective review included age,
gender, follow-up (months), pathological tumour (pTNM) stage as
defined by the Union for International Cancer Control (UICC) (7),
grading, and adjuvant chemo- or radiotherapy. All these clinical,
pathological as well as clinical outcome data were retrospectively
analyzed and a comprehensive database was created. 
HRQoL assessment was conducted using italian versions of
EORTC QLQ-C30 and EORTC BLM-30 questionnaires (8). 
The study was approved by local Ethics Committees at each
center. 
Quality of life assessment. Patients were asked to complete both the
following questionnaire: i) The EORTC-QLQ-C30 is a 30-item
cancer-specific validated questionnaire, the most known tool for the
QoL assessment. The versions we used were culturally validated in
the italian language (male/female Italian version) and subjected to
psychometric validation. This 30-item questionnaire has multi-item
scales and single items reflecting the multidimensionality of the
QoL construct. It comprises five functional scales covering physical,
role, emotional, cognitive and social aspects, and one scale of global
health status/QoL. It also includes three multi-item symptom
scales of fatigue, nausea/vomiting and pain, and six single items that
deal with dyspnoea, insomnia, appetite loss, constipation, diarrhoea
and financial difficulties caused by the disease or its treatment. The
scores obtained were converted into a scale from 0 to 100 according
to the provisions of the EORTC manual: aiming to obtain more
useful and easily understandable statistical data. For functional and
overall scales, higher scores represent a better QoL outcome,
whereas for symptom and single-item scales, higher scores
correspond to more problems and a reduced QoL. 
ii) The EORTC-QLQ-BLM30 (specific for muscle-invasive
bladder cancer) is a module from the EORTC that specifically
evaluates the impact of RC and reconstructive surgery in terms of
HR-QoL. It is a 30-item questionnaire that includes questions related
to general symptoms for all patients, a specific section with questions
for patients with urinary diversion, questions on sexual function and
a series of questions on the emotional state. For symptoms/single
items, a higher score means a higher level of symptoms/problems.
There is still no psychometric validation for this questionnaire and
Italian linguistic validation has not been performed yet.
Statistical analysis. Statistical analyses were conducted using SAS
version 9.3 software (SAS Institute, Inc., Cary, NC, USA). Mean
values with standard deviations (±SD) were computed and reported
for age (years), follow-up (months), and for all items included in
the EORTC.
Wilcoxon two-sample test was used to verify differences between
continuous variables, whereas Chi-square test was used to compare
categorical variables.
Statistical significance was achieved when the two-sided p-value
was 0.05 or less.
Results
This multicentric study was conducted on 145 patients (112
males and 33 females) who underwent RC and IC in five
urological academic centres. Patient characteristics are
reported in Table I.
The two groups were comparable with regard to the
clinical and demographical variables.
The EORTC- QLQ C30 data regarding our series are
reported in Table II, and those for EORTC-QLQ BLM-30 are
reported in Table III.
Our data showed that women with IC presented significantly
greater problems than men in cognitive functioning (higher
score means better functionally: 77.3±27.9 vs. 87.8±18.6,
respectively, p=0.04) as well in future perspective (lower score
means a low level of symptomatology/problems: 42.4±34.4 vs.
21.9±24.6, respectively, p=0.001). Nevertheless, men
undergoing IC had more problems in sexual functioning than
women (23.3±24.5 vs. 7.0±20.3, respectively, p=0.001).
Discussion
In 1948, the World Health Organization defined health as
being not only the absence of disease and infirmity, but also
the presence of physical, mental and social well-being (9).
Nevertheless. according to this definition, HR-QoL refers to
a multidimensional concept, including physical, social and
psychological wellbeing of the person, changing over time
and influenced by expectations, concerns and experiences.
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Every perturbance of the health status has a major impact on
a patient’s daily and personal life, leading to difficulty in
social and working activities and to frustration. The duty of
care of physicians is not limited to obtaining physical health,
but also concerns maintaining a patient’s capacity to fulfill
family, social and working roles. 
The urological literature emphasizes the importance of HR-
QoL in patients undergoing RC and urinary diversion; the ideal
form of urinary diversion after RC should be easy to handle,
presenting few complications, with low mortality and
morbidity, protecting upper urinary tract function and e the
ensuring the best possible HRQoL. Unfortunately, only few
studies have compared HRQoL between female and male
patients undergoing RC, who present different types of post-
operative complications and impact on daily and personal life.
In our series, at a mean ideal follow-up of 40 months, well
after the time for stabilization of QoL hypothesized by
Kulaksizoglu et al. (12 months), female patients undergoing
RC and IC showed a more severe impact on cognitive
function and future perspective, but a lower burden on their
sexual life (10). Our results on sexual life in patients with IC
agree with the literature data.
In 2004, Protogerou et al. evaluated 108 recurrence-free
patients undergoing RC and IC and S-pouch (with a control
group) using the EORTC- QLQ C30 questionnaire. The
patients of the IC group reported worse urinary function, but
sexual dysfunction, similar for the groups, was less important
in women compared with the male population (11), as
reported in our series. These data were confirmed by
Hedgepeteh et al., who evaluated 336 patients undergoing
RC and IC or ONB or simple cystoscopy using the Bladder
Cancer Index (12) and the EORTC Body Image Scale (13).
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Table I. Centre, age and pathological and clinical characteristics of 145
patients with ileal conduit according to gender. 
Characteristic                                        Males             Females     p-Valuea
                                                                                           
No. of patients                                        112                   33                 
Centre, n (%)                                                                                        
  Naples                                              30 (26.8)           2 (6.1)             
  Padua                                               16 (14.3)          7 (21.2)            
  Rome                                               25 (22.3)          5 (15.1)            
  Trieste                                              15 (13.4)          6 (18.2)            
  Verona                                             26 (23.2)         13 (39.4)          ns
Mean age (±SD), years                    71.0 (±8.2)      70.5 (±8.7)        ns
Mean follow-up (±SD), months     41.8 (±34.4)    52.5 (±40.5)       ns
Stage (pTNM-UICC), n (%)                                                                
  Stage 0-I                                          38 (33.9)         11 (33.3)           
  Stage II                                            34 (30.4)          7 (21.2)            
  Stage III+IV                                    40 (35.7)         15 (45.5)          ns
Grading, n (%)                                                                                     
  Gx                                                      1 (0.9)                  --                  
  G1-2                                                  8 (7.1)             2 (6.1)             
  G3-4                                               103 (92.0)        31 (93.9)          ns
Adjuvant chemotherapy, n (%)*                                                         
  No                                                    84 (77.8)         25 (75.8)           
  Yes                                                   24 (22.2)          8 (24.2)           ns
Adjuvant radiotherapy, n (%)*                                                            
  No                                                   102 (92.7)        32 (97.0)           
  Yes                                                     8 (7.3)             1 (3.0)            ns
*Totals may not agree due to missing values. aWilcoxon two-sample
test or Chi-square test were used as appropriate (females vs. males). SD:
standard deviation; ns: not significant (p>0.05).
Table II. Mean and standard deviation (±SD) of scores for the QLQ-
C30 functional and single items according to gender of 145 patients
with ileal conduit.
Item                                                  Males               Females       p-Valuea
                                                       (N=112)              (N=33)               
                                                    Mean (±SD)      Mean (±SD)          
Physical functioning*                73.9 (±25.2)      75.4 (±24.0)         ns
Role functioning*                      78.4 (±28.9)      72.2 (±29.4)         ns
Emotional functioning*             80.5 (±23.0)      72.7 (±30.1)         ns
Cognitive functioning*              87.8 (±18.6)      77.3 (±27.9)       0.04
Social functioning*                    84.7 (±22.8)      80.3 (±23.7)         ns
Fatigue§                                      29.1 (±26.6)      31.0 (±30.1)         ns
Nausea and vomiting§                 5.2 (±14.5)         2.5 (±7.4)           ns
Pain§                                           11.8 (±17.6)       13.1(±21.1)         ns
Dyspnoea§                                  20.5 (±26.2)      21.2 (±31.0)         ns
Insomnia§                                   19.3 (±27.8)      22.2 (±27.2)         ns
Appetite loss§                             15.2 (±28.3)      12.1 (±26.1)         ns
Constipation§                              33.3 (±34.7)      27.3 (±35.8)         ns
Diarrhoea§                                   8.6 (±20.4)       10.1 (±27.0)         ns
Financial difficulties§                15.6 (±26.8)      10.1 (±17.6)         ns
Global quality of life scale§      62.5 (±24.3)      60.9 (±29.2)         ns
*A higher score represents a higher level of functioning. §A higher score
means a higher level of symptomatology/problems. aWilcoxon two-
sample test (females vs. males). Ns: not significant (p>0.05).
Table III. Mean and standard deviation (±SD) of scores for the QLQ-
BLM30 items according to gender of 145 patients with ileal conduit.
Item                                                  Males               Females       p-Valuea
                                                       (N=112)              (N=33)               
                                                    Mean (±SD)      Mean (±SD)
Future perspective§                    21.9 (±24,6)      42.4 (±34.4)      0.001
Abdominal bloating 
and flatulence§                          24.7 (±24.9)      26.3 (±31.5)         ns
Body image§                               29.6 (±28.8)      28.3 (±33.1)         ns
Sexual functioning§                   23.3 (±24.5)       7.0 (±20.3)       0.001
Sex life§                                      80.8 (±33.7)      75.0 (±50.0)         ns
§A higher score means a higher level of symptomatology/problems.
aWilcoxon two-sample test (females vs. males). Ns: not significant
(p>0.05).
They documented higher sexual functional scores in female
patients (p=0.021) and generally worse for patients with
conduit (14).
In our study, women reported better sexual function in
comparison with male patients; female sexual function may be
influenced by body perception and changes in body image,
whereas male patients may experience problems in erectile
function and ejaculatory function (15). The absence of
ejaculation, obviously affecting only male patients, can deeply
affect sexual QoL of the patients, as documented by Mak et al.,
comparing patients affected by muscle-invasive bladder cancer
and treated with RC or bladder-sparing trimodal therapy (15).
Moreover, in 2006, Allareddy et al. evaluated QoL in
long-term surviving patients undergoing RC using the
Functional Assessment of Cancer Therapy (FACT-BL)
instrument (16). At multivariate analysis, male patients had
globally higher QoL life scores in comparison with female
patients, but male patients had a worse social and well-being
score in the stage II population (17).
With regard to the concerns about future and cognitive
function, no literature studies documented differences
between male and female patients; nevertheless, Cerruto et
al., in a systematic review of QoL after RC, showed that
study populations with more than 65% of men had a better
HR-QoL, but only in the ONB subgroup (5).
Although not significant, 45% of the female patients vs.
35% of the male patients had clinical stage III-IV disease,
which can negatively influence QoL and concerns about future
perspective and future disease recurrence in this population.
Our study presents several biases: a relatively limited
number of patients, although our findings agree with
literature data, and the absence of a baseline evaluation;
nevertheless, the use of validated questionnaires make our
results reliable and comparable.
Larger and prospective studies using validated questionnaires
are needed, with the aim of easily comparing QoL between men
and women undergoing RC; in addition, the use of specific
questionnaires, such as the IONB-PRO, should be encouraged
in order to address the specific problems and concerns related
to the type of urinary diversion (18).
Conclusion 
In our series of 145 patients undergoing IC, female patients
present greater burden than male patients in cognitive
functioning, as well in future perspective, but lesser concerns
with regard to sexual function. Larger and randomized
studies are needed, with the aim of better understanding the
aetiology of these differences.
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